Literature DB >> 17997341

Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders.

B Viollet1, R Mounier, J Leclerc, A Yazigi, M Foretz, F Andreelli.   

Abstract

In the light of recent studies in humans and rodents, AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine protein kinase, has been described as an integrator of regulatory signals monitoring systemic and cellular energy status. AMP-activated protein kinase (AMPK) has been proposed to function as a 'fuel gauge' to monitor cellular energy status in response to nutritional environmental variations. Recently, it has been proposed that AMPK could provide a link in metabolic defects underlying progression to the metabolic syndrome. AMPK is a heterotrimeric enzyme complex consisting of a catalytic subunit alpha and two regulatory subunits beta and gamma. AMPK is activated by rising AMP and falling ATP. AMP activates the system by binding to the gamma subunit that triggers phosphorylation of the catalytic alpha subunit by the upstream kinases LKB1 and CaMKKbeta (calmodulin-dependent protein kinase kinase). AMPK system is a regulator of energy balance that, once activated by low energy status, switches on ATP-producing catabolic pathways (such as fatty acid oxidation and glycolysis), and switches off ATP-consuming anabolic pathways (such as lipogenesis), both by short-term effect on phosphorylation of regulatory proteins and by long-term effect on gene expression. As well as acting at the level of the individual cell, the system also regulates food intake and energy expenditure at the whole body level, in particular by mediating the effects of insulin sensitizing adipokines leptin and adiponectin. AMPK is robustly activated during skeletal muscle contraction and myocardial ischaemia playing a role in glucose transport and fatty acid oxidation. In liver, activation of AMPK results in enhanced fatty acid oxidation as well as decreased glucose production. Moreover, the AMPK system is one of the probable targets for the anti-diabetic drugs biguanides and thiazolidinediones. Thus, the relationship between AMPK activation and beneficial metabolic effects provide the rationale for the development of new therapeutic strategies in metabolic disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17997341     DOI: 10.1016/j.diabet.2007.10.004

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  53 in total

1.  AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages.

Authors:  Yun Wang; Benoit Viollet; Robert Terkeltaub; Ru Liu-Bryan
Journal:  Ann Rheum Dis       Date:  2014-10-31       Impact factor: 19.103

2.  Targeting therapeutic effects: subcellular location matters. Focus on "Pharmacological AMP-kinase activators have compartment-specific effects on cell physiology".

Authors:  Judy Creighton
Journal:  Am J Physiol Cell Physiol       Date:  2011-09-28       Impact factor: 4.249

3.  Development of novel adenosine monophosphate-activated protein kinase activators.

Authors:  Jih-Hwa Guh; Wei-Ling Chang; Jian Yang; Su-Lin Lee; Shuo Wei; Dasheng Wang; Samuel K Kulp; Ching-Shih Chen
Journal:  J Med Chem       Date:  2010-03-25       Impact factor: 7.446

Review 4.  Exposure to ambient air particulate matter and non-alcoholic fatty liver disease.

Authors:  Giovanni Tarantino; Domenico Capone; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

5.  Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.

Authors:  Tian Shen; Bilin Xu; Tao Lei; Lin Chen; Cuiping Zhang; Zhenhua Ni
Journal:  Exp Ther Med       Date:  2018-08-01       Impact factor: 2.447

6.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

Review 7.  Effects of AMP-activated protein kinase in cerebral ischemia.

Authors:  Jun Li; Louise D McCullough
Journal:  J Cereb Blood Flow Metab       Date:  2009-12-16       Impact factor: 6.200

8.  Fat accumulation in Caenorhabditis elegans triggered by the electrophilic lipid peroxidation product 4-hydroxynonenal (4-HNE).

Authors:  Sharda P Singh; Maciej Niemczyk; Ludwika Zimniak; Piotr Zimniak
Journal:  Aging (Albany NY)       Date:  2008-12-18       Impact factor: 5.682

9.  Is impaired energy regulation the core of the metabolic syndrome in various ethnic groups of the USA and Taiwan?

Authors:  Mark L Wahlqvist; Hsing-Yi Chang; Chu-Chih Chen; Chih-Cheng Hsu; Wan-Chi Chang; Wuan-Szu Wang; Chao A Hsiung
Journal:  BMC Endocr Disord       Date:  2010-06-01       Impact factor: 2.763

10.  Genetic variants in human CLOCK associate with total energy intake and cytokine sleep factors in overweight subjects (GOLDN population).

Authors:  Marta Garaulet; Yu-Chi Lee; Jian Shen; Laurence D Parnell; Donna K Arnett; Michael Y Tsai; Chao-Qiang Lai; Jose M Ordovas
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.